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AbstrACt 
Objectives To assess the prevalence of mild-to-moderate 
distress in patients with end-stage renal disease (ESRD) 
and determine the association between distress and 
patient characteristics.
Design Cross-sectional survey using emotion 
thermometer and distress thermometer problem list.
setting Renal units in four hospital Trusts in the West 
Midlands, UK.
Participants Adult patients with stage 5 chronic kidney 
disease who were: (1) On prerenal replacement therapy. 
(2) On dialysis for less than 2 years. (3) On dialysis for 2 
years or more (4) With a functioning transplant.
Outcomes The prevalence of mild-to-moderate distress, 
and the incidence of distress thermometer problems and 
patient support needs.
results In total, 1040/3730 surveys were returned (27.9%). 
A third of survey respondents met the criteria for mild-to-
moderate distress (n=346; 33.3%). Prevalence was highest 
in patients on dialysis for 2 years or more (n=109/300; 
36.3%) and lowest in transplant patients (n=118/404; 29.2%). 
Prevalence was significantly higher in younger versus older 
patients (χ2=14.33; p=0.0008), in women versus men 
(χ2=6.63; p=0.01) and in black and minority ethnic patients 
versus patients of white ethnicity (χ2=10.36; p=0.013). Over 
40% of patients (n=141) reported needing support. More 
than 95% of patients reported physical problems and 91.9% 
reported at least one emotional problem.
Conclusions Mild-to-moderate distress is common in 
patients with ESRD, and there may be substantial unmet 
support needs. Regular screening could help identify 
patients whose distress may otherwise remain undetected. 
Further research into differences in distress prevalence 
over time and at specific transitional points across the 
renal disease pathway is needed, as is work to determine 
how best to support patients requiring help.
bACkgrOunD
In 2016, there were 51 672 patients with 
end-stage renal disease (ESRD) receiving 
renal replacement therapy (RRT) in 
England.1 Treatment is life-sustaining but 
not curative, and patients must constantly 
adjust to frequent changes to health status 
and likelihood of survival. Consequently, 
patients can experience many emotional and 
psychological stressors, including acceptance 
of diagnosis, disease progression, choosing 
treatment options, coping with dialysis and 
associated impacts on employment, rela-
tionships and lifestyle.2 3 Evidence suggests 
that patients with ESRD experience rates of 
depression and anxiety markedly higher than 
the general population.4 5 Establishing prev-
alence is challenging, partly because many 
uraemic symptoms can be misinterpreted as 
symptoms of depression,6 and partly due to 
the variation in prevalence estimates obtained 
using different diagnostic tools and modes 
of assessment (eg, self-reported vs inter-
view-based scales).7 Consequently, depression 
strengths and limitations of this study
 ► This study is the first to explore the prevalence of 
mild-to-moderate distress in a large cohort of pa-
tients with end-stage renal disease (ESRD).
 ► Findings suggest that distress affects around a third 
of patients with ESRD at any one time, and that 
there are substantial unmet support needs in this 
population.
 ► The inclusion of multiple study sites is likely to have 
minimised any bias arising from variations in the or-
ganisation and delivery of renal services.
 ► The survey response rate was low, and younger pa-
tients, those from black and minority ethnic groups 
and patients who had been more recently diagnosed 
were under-represented in responses.
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and anxiety prevalence estimates reported in the ESRD 
literature range from around 6% to 71%,8 but are gener-
ally considered to be between 20% and 30% for dialysis 
patients9 and around 25% for transplant patients.10 This 
compares to a point prevalence of depression of between 
2% and 9% and lifetime depression risk of around 7% in 
the general population.11 
Untreated anxiety and depression in patients with 
ESRD are associated with decreased health-related quality 
of life and higher symptom burden.12 These factors may 
raise the risk of poor outcomes, increased healthcare 
use and suboptimal adherence with diet and medication 
regimes.13–15 There is also evidence that depression status 
is associated with an elevated risk of all-cause mortality 
in renal patients, with meta-analysis suggesting an excess 
mortality risk attributable to depression higher than 
that observed in other chronic diseases such as cancer 
and diabetes.7 Provision of emotional and psychological 
support is central to the recommended management of 
renal disease, and both the UK Department of Health 
and National Institute for Health and Care Excellence 
mandate provision of such support within national renal 
guidelines.16 17
While supportive services are relatively advanced for 
those with higher-level needs requiring psychiatric or 
psychological intervention, there is a lack of robust data 
on the prevalence of lower-level support needs—defined 
as difficulties adjusting to, and coping effectively with, 
renal failure, diagnosis, physical symptoms and treat-
ment. It may also be useful to broaden the focus beyond 
narrowly defined anxiety and depression to consider 
the determinants and consequences of more general 
emotional and psychological difficulty encompassed 
by the term ‘distress’. While linear progression from 
lower-level to severe difficulty is not inevitable, timely 
identification of patient distress may facilitate effective 
management. This study aimed to assess the prevalence 
of mild-to-moderate distress in a cohort of patients with 
ESRD and determine the association between distress 
and sociodemographic and clinical characteristics. It 
forms part of a larger mixed-methods study that aims to 
understand how the recognition and management of 
patients’ emotional and psychological support needs can 
be integrated into the ESRD pathway.18
Methods
The study used a cross-sectional survey, distributed by 
post to all eligible patients with ESRD managed at four 
National Health Service hospital Trusts in the West 
Midlands, UK. Trusts were chosen to maximise diversity 
in patient demographics, catchment size, urban-rural mix 
and the organisation of psychological support services: 
site 1 (small) and site 2 (large) both serve urban, inner 
city catchments with substantial black and minority ethnic 
(BME) populations. Site 3 (medium) and site 4 (large) 
both serve predominantly white populations in urban 
areas with surrounding rural districts. Sites 2 and 4 have 
access to a renal psychologist for the provision of psycho-
logical support services, whereas sites 1 and 3 do not.
Participants and recruitment
Eligible patients were aged 18+ years, diagnosed with 
stage 5 chronic kidney disease (CKD), and grouped 
according to their stage on the ESRD pathway: (1) 
Pre-RRT. (2) On peritoneal or haemodialysis for less than 
2 years. (3) On dialysis for 2 years or more. (4) With a func-
tioning transplant. Although differentiating according to 
dialysis vintage is not a recognised clinical distinction, it 
was hypothesised by the clinicians involved in designing 
this study that there may be differences in distress prev-
alence between patients initiating dialysis more recently 
versus those undergoing dialysis for longer. Patients using 
psychiatric services since stage 5 CKD diagnosis were 
excluded. Renal unit staff at each Trust identified eligible 
patients from hospital records, and survey packs were 
prepared on Trust premises by the university research 
team. Eligible patients received a letter of invitation from 
the renal unit’s lead consultant, an information sheet 
and a survey, to be returned directly to the researchers. 
Return envelopes were marked with a unique identifier 
for recording returns, and non-responders received one 
reminder after 6 weeks. Mailings were carried out between 
January 2016 and May 2017.
Survey
The survey measured distress with emotion thermome-
ters (ETs),19 20 which use a Visual Analogue Scale covering 
five domains: distress, anxiety, depression, anger and 
perceived need for help. Patients score each domain on 
an 11-point Likert Scale to rate their levels of emotional 
upset during the preceding week, where ‘0’ corresponds 
to none and ‘10’ denotes extreme problems. Although 
not validated specifically for use with renal patients, the 
ET has been widely used in studies of patients with cancer 
and other chronic conditions where it has been found to 
be sensitive in identifying emotional difficulty and broadly 
defined distress.19 It incorporates the distress thermom-
eter (DT), which has been validated in the UK population 
with CKD.21 The survey also included the DT problem 
list22 which lists 36 problems across five domains: practical 
(n=5), family (n=3), emotional (n=6), spiritual (n=1) and 
physical (n=21). Patients indicated which (if any) of the 
36 problems they had experienced in the previous week. 
Closed questions covered sociodemographic characteris-
tics (age, sex, ethnicity) and treatment modality (where 
relevant).
Data analysis
Thresholds for distress using the ET have been vali-
dated,19 20 with a score of 4–5 denoting mild distress, and 
6–7 denoting moderate distress. Patients were defined 
as having mild-to-moderate distress if they: (1) Scored 
between 4 and 7 on the DT (regardless of scores in the 
other ET domains), or (2) scored 0– 3 on the DT and 
4–7 on one or more of the anxiety, depression and anger 
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thermometers, with no thermometer exceeding 7. Anal-
ysis was descriptive, focusing on associations between 
distress and respondents’ stage on the ESRD pathway 
and sociodemographic characteristics. Anonymised data 
were obtained from hospital information systems to allow 
a comparison of the characteristics of respondents and 
non-respondents on the basis of age group, sex, ethnic 
group and ESRD pathway stage. Comparisons were under-
taken using χ2 analysis. Any surveys in which the ETs were 
left blank by a respondent were excluded from analysis. 
The prevalence of total and individual problems from the 
DT problem list were analysed descriptively, and medians 
and IQRs were calculated to compare numbers of prob-
lems cited within each domain. Data were analysed using 
SPSS V.21.0 (IBM Corp, Armonk, New York, USA).
Sample size
The primary outcome was the difference in the prevalence 
of mild-to-moderate distress across patients at different 
ESRD stages. We anticipated an average prevalence of 
25% across all patients,9 with patients in the stages with 
the highest and lowest prevalence at ±5% points from this 
average (ie, 20% for the stage with the lowest prevalence 
and 30% for the stage with the highest prevalence). This 
equated to a small effect size (w) of approximately 0.1. 
To detect this difference with 80% power and 5% signifi-
cance, a total of 1090 responses were required (assuming 
approximately equal numbers of patients in each ESRD 
stage).
Patient and public involvement
The study design and research questions were developed 
with inputs from a study advisory group that included 
patient representatives, and the patient and public involve-
ment group attached to the chronic diseases theme of 
Collaboration for Leadership in Applied Health Research 
and Care (CLAHRC) West Midlands. These groups were 
also involved in selecting appropriate outcome measures 
that optimised data quality while minimising participant 
burden. Patients were not involved in recruitment to the 
study or its conduct. Study participants will be sent a plain 
English summary of final study results if they indicated 
during the informed consent process that they would like 
to receive this.
results
A total of 3730 surveys were sent across the four study 
sites. One hundred patients died between the initial and 
reminder mailings (2.7%) and 2442 recipients (65.5%) 
did not respond. Of the 1188 responses received (31.8%), 
148 were removed due to non-completion of ETs (4.0%), 
giving a total of 1040 valid responses (27.9%) (figure 1). 
Rates of valid responses ranged from 23.0% in site 1% 
to 30.4% in site 4. Younger patients (<65 years old) were 
significantly less likely to respond than those aged 65 years 
and over, as were those from BME groups compared with 
those in the white ethnic group. Patients yet to begin RRT 
and those on dialysis for less than 2 years were significantly 
less likely to respond than patients with a transplant or 
who had been undergoing dialysis for 2 years or more. 
There was no significant difference between responders 
and non-responders on the basis of sex (table 1).
Characteristics of respondents
The majority of respondents were male (n=633; 60.9%) 
and in the white ethnic group (n=902; 86.7%) (table 2). 
Patients aged between 51 years and 69 years constituted 
the largest age group (n=441; 42.9%), with those aged 
under 50 years comprising 16.9% of the total (n=174). 
Nearly two-fifths of respondents had received a trans-
plant (n=404; 38.8%) and 28.8% had been on dialysis for 
2 years or more (n=300). Of the 454 patients undergoing 
Figure 1 Surveys mailed and returned.
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regular dialysis, the most common modality was hospital/
incentre haemodialysis (n=343; 75.6%).
Prevalence of distress
A total of 561 respondents (53.9%) were categorised as 
having none-to-low distress, and a further 133 patients 
(12.3%) met the criteria for severe distress (ie, scoring 
>7 on one or more of the ETs). A total of 346 respon-
dents (33.3%) met the criteria for mild-to-moderate 
distress (hereafter termed ‘distress’). Distress prevalence 
by hospital site was lowest in site 4 (30.9%) and highest in 
site 1 (38.5%), although the difference between study sites 
was not statistically significant (χ2=3.24; p=0.356). Distress 
was identified in 208 patients (60.1%) on the basis of their 
DT score alone, with the remaining 138 (39.9%) identi-
fied from their scores on the anxiety, depression or anger 
thermometers. Distress prevalence was highest in patients 
who had been on dialysis for 2 years or more (n=109/300; 
36.3%) and lowest in transplant patients (n=118/404; 
29.2%). For dialysis modality, distress was most prevalent 
for home haemodialysis patients (n=13/31; 41.9%) and 
lowest in the peritoneal dialysis group (n=22/80; 27.5%), 
although numbers were small. There was no significant 
difference in rates of distress on the basis of ESRD stage 
or dialysis type when groups were compared. In contrast, 
all sociodemographic characteristics showed signifi-
cant differences in distress prevalence between groups. 
Patients in the youngest age group were significantly 
more likely to report distress than those in the older age 
groups (n=78/174; 44.8%; χ2=14.33; p=0.0008). The prev-
alence of distress was significantly higher for women than 
men (38.1% vs 30.2%; χ2=6.63; p=0.01) and for BME 
patients compared with white patients (45.7% vs 31.4%; 
χ2=10.36; p=0.0013).
Perceived need for help
Scores on the ‘need’ thermometer were assessed as an 
outcome measure indicating patients’ perceived need for 
help. Scores of 4 and above were considered to indicate 
unmet support needs19 (table 3). Patients at study sites 1 
and 3 had significantly higher perceived support needs 
than those in sites 2 and 4 (29.4% and 22.9% vs 21.5% 
and 20.1%; χ2=9.49; p=0.02). There were also significant 
differences by subgroup according to ESRD stage: 66.0% 
of patients on dialysis for less than 2 years (n=35) required 
support, as did 55.7% of patients on dialysis for 2 years or 
more (n=59). Perceived support needs in the pre-RRT 
and transplant groups were significantly lower, at 34.9% 
and 29.9% respectively (χ2=27.71; p<0.0001). Support 
needs were also significantly higher in BME compared 
with white patients, at 57.6% vs 37.9% (χ2=7.06; p=0.008).
Dt problem list
All but six patients reported experiencing at least one 
problem on the DT problem list in the preceding week 
(98.0%) (table 4). The most frequently reported prob-
lems were all in the emotional and physical domains, 
with 91.9% of patients reporting at least one emotional 
problem in the previous week, and 95.1% reporting at 
least one physical problem. ‘Worry’ was the the most 
common problem across all domains (n=247; 74.3%). 
‘Fatigue’ (71.7%), ‘dry/itchy skin’ (65.0%) and ‘sleep’ 
Table 1 Comparison of the characteristics of survey responders and non-responders
Characteristic Respondents (%) Non-respondents (%) Total
Comparison of 
proportions
Stage on ESRD pathway
  Pre-RRT 183 (24.6) 560 (75.4) 743 χ2=9.96; p=0.02
  Dialysis <2 years 162 (25.2) 481 (74.8) 643
  Dialysis 2+ years 293 (30.0) 684 (70.0) 977
  Transplant 402 (29.4) 965 (70.6) 1367
Age group*
  Less than 65 years 503 (24.7) 1537 (75.3) 2040 χ2=19.86; p<0.0001
  65 years and above 524 (31.3) 1151 (68.7) 1675
Sex
  Male 635 (28.0) 1636 (72.0) 2271 χ2=0.01; p=0.92
  Female 405 (27.8) 1054 (72.2) 1459
Ethnicity†
  White 902 (34.4) 1720 (65.6) 2622 χ2=76.16; p<0.0001
  Black and minority 
ethnic
138 (17.9) 635 (82.1) 773
*Age unknown for 15 patients; 
†Ethnicity unknown for 335 patients;
Bold text indicates statistical significance.
ESRD, end-stage renal disease; RRT, renal replacement therapy.
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(61.3%) were the most common physical problems. ‘Spir-
itual problems’ (6.6%) and ‘problems with childcare’ 
(family domain: 3.8%) were reported least frequently. 
The median number of total problems reported was 
12/36 (IQR: 7 to 16) (table 5).
Subgroup analysis shows that transplant patients 
reported significantly fewer physical problems and total 
problems than pre-RRT or dialysis patients (median 
physical problems 6/21, IQR 3 to 10, p=0.019; median 
total problems 10/36, IQR 5 to 16, p=0.023). Patients 70 
years and older reported significantly fewer problems 
on the practical, family and emotional domains than 
younger patients. They also reported significantly fewer 
total problems. Women reported significantly more phys-
ical problems than men (median 8/21, IQR 5 to 12 vs 
7/21, IQR 5 to 11; p=0.043).
DisCussiOn
Detecting distress is important for the optimal care of 
patients with ESRD, and evidence suggests that reducing 
emotional and psychological difficulties may enhance 
well-being and improve patients’ ability to engage 
with complex and demanding treatments. Our study 
has shown that as many as one in three patients with 
ESRD may have mild-to-moderate distress, and rates of 
reporting emotional and physical problems were high. 
This was evident across the ESRD pathway, with around 
35% of pre-RRT and dialysis patients and 29% of trans-
plant patients meeting the criteria for mild-to-moderate 
distress. The finding that the prevalence of distress was 
almost as high in transplant patients as those undergoing 
dialysis suggests that although they may experience fewer 
physical problems, the need for ongoing psychological 
Table 2 Respondent characteristics and proportion by sub-group with mild-to-moderate distress
Characteristic Respondents (%)
Mild-to-moderate distress 
(%)
Comparison of proportions 
(mild-to-moderate distress 
patients)*
  All respondents 1040 (100.0) 346 (33.3)
Study site
  Site 1 187 (18.0) 72 (38.5) χ2=3.24; p=0.356
  Site 2 177 (17.0) 58 (32.8)
  Site 3 323 (31.1) 107 (33.1)
  Site 4 353 (33.9) 109 (30.9)
Stage on ESRD pathway
  Pre-RRT 182 (17.5) 64 (35.2) χ2=4.85; p=0.183
  Dialysis <2 years 154 (14.8) 55 (35.7)
  Dialysis 2+ years 300 (28.8) 109 (36.3)
  Transplant 404 (38.8) 118 (29.2)
Dialysis type (n=454)
  Hospital/incentre 
haemodialysis
343 (75.6) 129 (37.6) χ2=3.36; p=0.186
  Home haemodialysis 31 (6.8) 13 (41.9)
  Peritoneal dialysis 80 (17.6) 22 (27.5)
Age group†
  Less than 50 years 174 (16.9) 78 (44.8) χ2=14.33; p=0.0008
  50–69 years 441 (42.9) 145 (32.9)
  70 years and above 414 (40.2) 119 (28.7)
Sex
  Male 633 (60.9) 191 (30.2) χ2=6.63; p=0.01
  Female 407 (39.1) 155 (38.1)
Ethnicity
  White 902 (86.7) 283 (31.4) χ2=10.36; p=0.0013
  Black and minority ethnic 138 (13.3) 63 (45.7)
*Bold text denotes a statistically significant difference between groups; 
†Age unknown for four respondents
ESRD, end-stage renal disease; RRT, renal replacement therapy.
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adjustment does not end at the point of transplantation.10 
Mild-to-moderate distress was most prevalent in the 
group of patients who had been on dialysis for 2 years or 
more (36.3%), which may reflect a lack of adjustment 
and coping in this group with the ongoing challenges of 
undergoing regular dialysis treatment over an extended 
period, potentially declining health, and the limitations 
that dialysis treatment places on family, relationships 
and lifestyle. There was also variation by dialysis type, 
with patients receiving hospital/incentre haemodialysis 
reporting distress rates of 37.6%, compared with 27.5% 
for patients undergoing peritoneal dialysis. Numbers 
were too small to detect statistically significant differ-
ences, but this distinction has been found elsewhere,23 
and would benefit from further study.
Distress prevalence was strongly associated with socio-
demographic characteristics and was significantly higher 
in younger versus older patients, in BME versus white 
patients and in women compared with men. These trends 
have also been found in studies of anxiety and depression 
in renal patients.24 25 There are numerous psychological 
theories of health and illness which may have a role in 
explaining patients’ variable responses to ESRD diagnosis 
and treatment.26–28 These theories emphasise that experi-
ence of distress is likely to be determined by an individ-
ual’s personal degree of resilience and individual coping 
resources rather than being associated with specific clin-
ical characteristics.
Comparable national figures for the pre-RRT group 
are not available, but if the prevalence of mild-to-mod-
erate distress found in this study was standardised to 
the current population in England with a functioning 
transplant or undergoing dialysis, it would equate to 
18 970 patients with ESRD experiencing difficulties, 
of whom 7835 may want help.1 It has been argued that 
the primary goal of supportive services should be to 
Table 3 Perceived need for help with distress by subgroup with mild-to-moderate distress (n=346)
Characteristic Median ‘need’ score (IQR)
Patients scoring 4 or more 
on need thermometer (%)
Comparison of proportions 
(mild-to-moderate distress 
patients)*
  All respondents 3 (1 to 5) 141 (40.8)
Study site
  Site 1 1 (0 to 4) 55 (29.4) χ2=9.49; p=0.02
  Site 2 1 (0 to 3) 38 (21.5)
  Site 3 1 (0 to 3) 74 (22.9)
  Site 4 0 (0 to 3) 71 (20.1)
Stage on ESRD pathway
  Pre-RRT 2 (0 to 4) 22 (34.9) χ2=27.71; p<0.0001
  Dialysis <2 years 3 (2 to 6) 35 (66.0)
  Dialysis 2+ years 4 (2 to 6) 59 (55.7)
  Transplant 2 (0 to 4) 35 (29.9)
Dialysis type (n=454)
  Hospital/in-centre 
haemodialysis
4 (2 to 6) 70 (56.0) χ2=5.44; p=0.07
  Home haemodialysis 4 (2 to 8) 7 (53.8)
  Peritoneal dialysis 3 (0 to 5) 6 (28.6)
Age group
  Less than 50 years 3 (2 to 5) 35 (44.9) χ2=0.85; p=0.654
  50–69 years 3 (1 to 5) 55 (39.0)
  70 years and above 3 (1 to 5) 48 (41.4)
Sex
  Male 3 (1 to 5) 73 (39.2) χ2=0.54; p=0.462
  Female 3 (1 to 5) 67 (43.8)
Ethnicity
  White 3 (1 to 5) 106 (37.9) χ2=7.06; p=0.008
  Black and minority ethnic 5 (2 to 7) 34 (57.6)
*Bold text indicates a statistically significant difference between groups.
ESRD, end-stage renal disease; RRT, renal replacement therapy.
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Table 4 Number and proportion of patients reporting problems on the distress thermometer problem list
Problems by domain Number of patients (%)*
Patients reporting at least one 
problem for the domain (%)
  Any problems (n=36) – 339 (98.0)
Practical domain (n=5)
  Transport 84 (24.3)
  Insurance/financial 76 (22.0)
  Work 53 (15.3) 167 (48.3)
  Housing 30 (8.7)
  Childcare 13 (3.8)
Family domain (n=3)
  Dealing with friend/relative 66 (19.1)
  Dealing with partner 60 (17.3) 118 (34.1)
  Dealing with children 27 (7.8)
Emotional domain (n=6)
  Worry 257 (74.3)
  Loss of interest in usual activities 186 (53.8)
  Sadness 166 (48.0) 318 (91.9)
  Depression 159 (46.0)
  Nervousness 150 (43.4)
  Fears 148 (42.8)
Spiritual domain (n=1)
  Spiritual/religious concerns 23 (6.6) –
Physical domain (n=21)
  Fatigue 248 (71.7)
  Skin dry/itchy 225 (65.0)
  Sleep 212 (61.3)
  Memory/concentration 183 (52.9)
  Pain 178 (51.4)
  Getting around 171 (49.4)
  Tingling in hands/feet 144 (41.6)
  Breathing 133 (38.4)
  Feeling swollen 127 (36.7)
  Bathing/dressing 119 (34.4) 329 (95.1)
  Appearance 116 (33.5)
  Eating 111 (32.1)
  Nose dry/congested 108 (31.2)
  Constipation 106 (30.6)
  Nausea 100 (28.9)
  Changes in urination 94 (27.2)
  Indigestion 92 (26.6)
  Sexual 88 (25.4)
  Diarrhoea 79 (22.8)
  Mouth sores 42 (12.1)
  Fevers 31 (9.0)
*Problems within each domain ranked from most to least frequently cited by respondents
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distinguish between transient and ongoing difficulties 
and focus on optimising patients’ ability to cope with 
their condition.29 In this context, it is likely that the most 
feasible supportive interventions are those that can be 
incorporated into routine clinical practice and standard 
protocols for ESRD care. ETs could be used regularly by 
clinicians during patient consultations or by renal nurses 
to screen for distress. Screening in itself will not neces-
sarily lead to better patient outcomes, but it may help to 
identify patients whose distress would otherwise remain 
undetected, and in doing so, could enable the targeted 
provision of support services.
Experiencing distress may be considered a normal 
response to chronic disease diagnosis, and not all 
patients with mild-to-moderate distress will want to 
receive support. The likelihood that patients with ESRD 
will experience symptoms of distress was predominantly 
associated with age, sex and ethnicity. Consequently, 
screening for distress would seem particularly important 
for younger patients, who may experience significantly 
greater disruption to their family and working life than 
older patients, women, and for patients in BME groups, 
who reported uniformly high rates of mild-to-moderate 
distress and high support needs. It may also be useful to 
target screening for distress towards those who undergo 
regular hospital or incentre haemodialysis. Providing 
appropriate information to patients early on in the ESRD 
pathway (pre-RRT) about the distress they may experi-
ence could also help to manage patients’ expectations and 
allow timely identification of emotional and psycholog-
ical difficulties. There was also evidence of a centre effect 
in the proportion of patients reporting a perceived need 
for support at participating study sites. Patients in sites 1 
and 3, where there is no access to a renal psychologist, 
reported significantly higher rates of support need than 
those in sites 2 and 4 where renal psychologist support 
is available. This suggests that the availability of inhouse 
psychological support services may play an important role 
in helping patients with ESRD to manage distress.
limitations
The survey response rate was low, and younger patients, 
those from BME groups and patients who had been more 
recently diagnosed were under-represented in responses. 
The study was marginally underpowered, with 1040 valid 
responses received, rather than the 1090 required by our 
a priori sample size estimation. We are also unable to say 
whether distress is more or less common in survey respon-
dents compared with non-respondents, nor could we 
perform detailed subgroup analyses for patients within 
each ESRD pathway stage. This meant that participants 
in each ESRD pathway stage were treated as a homoge-
neous cohort when in reality there may have been differ-
ences between them that may have impacted on their 
experience of distress such as issues with medication or 
ESRD-related complications like fistula failure, infec-
tion or transplant failure. However, in-depth qualitative 
research was undertaken with renal patients to explore 
the detailed determinants and consequences of their 
distress in a linked component of this study (findings to 
be reported elsewhere).
Nevertheless, our findings with regard to the patient 
groups most likely to experience distress were similar 
to existing evidence on anxiety and depression in renal 
disease. Because younger, BME patients were under-rep-
resented in our sample, the finding that patients in these 
groups reported significantly higher rates of mild-to-
moderate distress than older, white patients, suggests that 
we may have underestimated rather than overestimated 
overall distress prevalence. The inclusion of multiple 
study sites is likely to have minimised any bias that may 
arise from variations in the organisation and delivery of 
renal services. Patients referred to psychiatric services 
(as noted in their hospital record) were excluded, but 
we cannot know whether our sample included patients 
who had independently sought counselling or support 
via their general practitioner. The study was also cross-sec-
tional rather than longitudinal, and consequently allows 
limited understanding of the relationship between time 
since ESRD diagnosis and ability to cope with the resulting 
stressors. Some studies with renal patients have found 
no correlation between depressive symptoms and time 
since treatment initiation,9 whereas others have found a 
tendency for depression status to worsen.30 Future work 
using a cohort study design would aid understanding of 
the ways that individuals adapt to ESRD diagnosis and its 
ongoing management over time.
COnClusiOn
This study is, to our knowledge, the first to explore the 
prevalence of mild-to-moderate distress in a large cohort 
of patients with ESRD. Our findings show that mild-to-
moderate distress is common—even after transplanta-
tion—and there may be substantial unmet patient support 
needs. Further research into possible variations in distress 
prevalence over time and at different transitional points 
across the ESRD pathway is needed, as is work to deter-
mine how best to support patients requiring help.
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